



53850-Review.docx

Quotes Excluded  
Bibliography Excluded2%  
SIMILAR**Name of Journal:** *World Journal of Gastrointestinal Pathophysiology***Manuscript NO:** 53850**Manuscript Type:** REVIEW**Selective granulocyte and monocyte apheresis in inflammatory bowel disease: Its past, present and future**

Xiu-Li Chen, Jing-Wei Mao, Ying-De Wang

**Abstract**

The etiology and pathogenesis of inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's Disease (CD), are not fully understood so far. Therefore, IBD still remains incurable despite the fact that significant progress has been achieved in recent years in its treatment with innovative medicine. About 20 years ago, selective granulocyte and monocyte apheresis (CMA) was invented in Japan and later approved by the Japanese

## Match Overview

- | Rank | Source   | Words | Similarity |
|------|--|-------|------------|
| 1    | Crossref<br>Maria T. Abreu, Scott Plevy, Bruce E. Sands, Robert Weinstein. "Selective Leukocyte Apheresis for the Treatment of Infla ... | 35    | 1%         |
| 2    | Crossref<br>Koji Sawada. "Granulocyte and Monocyte Adsorptive Apheresis for Patients with Chronic Hepatitis C Virus Infection: A Re ...  | 31    | 1%         |
| 3    | Crossref<br>Satoshi Tanida, Tsutomu Mizoshita, Hirotada Nishie, Keiji Ozeki, Takahito Katano, Eiji Kubota, Hiromi Kataoka, Takeshi Ka    | 30    | 1%         |



国内版

国际版

Selective granulocyte and monocyte apheresis in inflamr



YJ



ALL

IMAGES

VIDEOS

12,600 Results

Any time ▾

## Inflammatory bowel disease: past, present, and future

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2780674>

In summary, a survey of the **past** and **present** advances in the inflammatory bowel **diseases** provides much cause for optimism. The accelerating pace of discovery in Crohn's **disease** and ulcerative colitis provides hope that each year will bring a better life to the growing number of individuals who suffer from these curious **diseases**.

Cited by: 295

Author: Bruce E. Sands

Publish Year: 2007

## Looking for predictive factors of clinical response to ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3583683>

Looking for predictive factors of clinical response to adsorptive **granulocyte and monocyte apheresis** in patients with ulcerative colitis: markers of response to GMA ... Mizoguchi E. Inflammatory bowel **disease**, **past, present** and the **future**: lessons from animal models. ... A retrospective search for predictors of clinical response to **selective** ...


Cited by: 16

Author: Yoko Yokoyama, Mikio Kawai, Ken Fukun...

Publish Year: 2013

Feedback





12,500 Results Any time ▾

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3583683>

Looking for predictive factors of clinical response to adsorptive **granulocyte and monocyte apheresis** in patients with ulcerative colitis: markers of response to GMA ... Mizoguchi E. Inflammatory bowel **disease**, **past, present** and the **future**: lessons from animal models. ... A retrospective search for predictors of clinical response to **selective** ...

**Cited by:** 16 **Author:** Yoko Yokoyama, Mikio Kawai, Ken Fukun...  
**Publish Year:** 2013

<https://link.springer.com/article/10.1007/s00535-006-1995-7>

Feb 16, 2007 · In summary, a survey of the **past** and **present** advances in the inflammatory bowel **diseases** provides much cause for optimism. The accelerating pace of discovery in Crohn's **disease** and ulcerative colitis provides hope that each year will bring a better life to the growing number of individuals who suffer from these curious **diseases**.

**Cited by:** 295      **Author:** Bruce E. Sands  
**Publish Year:** 2007

<https://paperity.org/p/21094840/inflammatory-bowel...>

Inflammatory bowel **disease: past, present, and future**. Journal of ... **Future** directions in the IBD will likely explicate the inhomogeneous causes of these **diseases**, with implications for individualized therapy. ... were found among 3000 patients treated for either multiple sclerosis or Crohns **disease** with this agent.<sup>90</sup> A second **selective** ...

**Cited by:** 295      **Author:** Bruce E. Sands  
**Publish Year:** 2007

<https://www.sciencedirect.com/science/article/pii/S1465324915000717>

Accordingly, **selective** depletion of these cells by adsorptive **granulocyte and monocyte apheresis** (GMA) with an Adacolumn has been applied as a non-pharmacologic treatment option for patients with active UC . . . . .

**Cited by:** 13      **Author:** Yoko Yokoyama, Kenji Watanabe, Hiroaki...  
**Publish Year:** 2015